Administration of intracoronary streptokinase during primary PCI for anterior STEMI with definite thrombosis improved the rate of TIMI 3 flow compared to no additional therapy (84% vs 58%, p=0.026).
Cohort (n=100)
Does intracoronary streptokinase improve coronary perfusion in patients with acute anterior STEMI and definite LAD thrombosis undergoing primary PCI?
Administration of intracoronary streptokinase during primary PCI for anterior STEMI with definite coronary thrombosis significantly improves angiographic markers of coronary perfusion.
Absolute Event Rate: 84% vs 58%
p-value: p=0.026
Background: The presence of intracoronary heavy thrombus burden during primary percutaneous coronary intervention (PCI) plays increases the incidence of occurrence no-reflow phenomenon. Intracoronary thrombolytic therapy during primary PCI may improve microvascular perfusion. The aim of this study was to assess the effect of using 250,000 U of intracoronary streptokinase during primary PCI in patients presenting with an acute anterior wall ST segment elevation myocardial infarction (STEMI) with a definite thrombus in the left anterior descending coronary artery (LAD) on clinical and angiographic outcomes. Methods: Prospective cohort study conducted on 100 patients managed by primary PCI within 12 hours of symptom onset. Patients were divided into a study group (n=50) that received intracoronary streptokinase during primary PCI, and a control group (n=50) that received no additional therapy. Post-procedural TIMI flow grade, myocardial blush grade (MBG), and corrected TIMI frame count were assessed. Admission and peak CK-MB and percentage of ST segment resolution were recorded. At 6-months follow-up, assessment for major adverse cardiovascular events (MACE) was performed. Results: There were no differences between both groups regarding baseline clinical characteristics, time to reperfusion, and risk factors for the development of coronary artery disease. Peak CK-MB was significantly higher in the control group (p = 0.004). In the study group, a larger proportion of patients had TIMI 3 flow at the end of the procedure 42 (84%) vs 29 (58%) – p = 0.026, and a larger proportion had MBG 2 and 3, 23 (46%) vs 17 (34%) and 24 (48%) vs 14 (28%), respectively – p = 0.001. Corrected TIMI frame count at the end of the procedure was significantly smaller in the study group 24.2 ± 4.97 vs 31.28 ± 6.7 frames (pConclusion: Administration of intracoronary streptokinase during primary PCI in patients presenting with acute anterior STEMI with definite coronary thrombosis improves coronary perfusion by improving TIMI flow grade, MBG, and shortening corrected TIMI frame count.
Emara et al. (2020) conducted a cohort in Acute anterior wall ST segment elevation myocardial infarction (STEMI) with definite coronary thrombosis (n=100). Intracoronary streptokinase vs. No additional therapy was evaluated on TIMI 3 flow at the end of the procedure (p=0.026). Administration of intracoronary streptokinase during primary PCI for anterior STEMI with definite thrombosis improved the rate of TIMI 3 flow compared to no additional therapy (84% vs 58%, p=0.026).